Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA069913-02
Application #
2113879
Study Section
Special Emphasis Panel (NSS)
Project Start
1995-07-01
Project End
1999-03-31
Budget Start
1996-04-01
Budget End
1997-03-31
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
O'Connor, Owen A; Portlock, Carol; Moskowitz, Craig et al. (2010) Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 16:719-26
Gerecitano, John; Portlock, Carol; Moskowitz, Craig et al. (2009) Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 146:652-5
O'Connor, Owen A; Moskowitz, Craig; Portlock, Carol et al. (2009) Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phas Br J Haematol 145:34-9
O'Connor, Owen A; Portlock, Carol; Moskowitz, Craig et al. (2008) A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol 143:201-9
Stubblefield, M D; Slovin, S; MacGregor-Cortelli, B et al. (2006) An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clin Oncol (R Coll Radiol) 18:410-8
Paoluzzi, Luca; O'Connor, Owen A (2006) Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs 20:13-23
Gerecitano, John; Goy, Andre; Wright, John et al. (2006) Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 134:391-8
Su, Yungpo Bernard; Vickers, Andrew J; Zelefsky, Michael J et al. (2006) Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. Cancer J 12:182-8
O'Connor, Owen A; Wright, John; Moskowitz, Craig et al. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-84
O'Connor, Owen A (2005) Developing new drugs for the treatment of lymphoma. Eur J Haematol Suppl :150-8

Showing the most recent 10 out of 16 publications